trending Market Intelligence /marketintelligence/en/news-insights/trending/mMeX-76IfRtPWVFNUCvoDA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Regeneron Q2 net income, revenues up YOY

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Regeneron Q2 net income, revenues up YOY

Regeneron Pharmaceuticals Inc. reported a 48% year over year increase in its second quarter non-GAAP net income to $487 million, or $4.17 per share.

The S&P Capital IQ normalized EPS consensus estimate for the second quarter was $3.18.

Second-quarter total revenues were also up 21% year over year to $1.47 billion.

"In the first half of 2017, we continued to bring our market-leading therapy EYLEA to more patients with retinal diseases, resulting in strong global sales. We also markedly expanded our positive impact on patient lives with two important new product launches for serious diseases, Dupixent for moderate-to-severe atopic dermatitis and Kevzara for moderately to severely active rheumatoid arthritis," Regeneron President and CEO Leonard Schleifer said in a statement.

The company's eye injection Eylea saw its U.S. net product sales grow to $919 million, up 11% year over year from $831 million.

On a GAAP basis, Regeneron's second-quarter net income of $388 million, or $3.34 a share, was up 98% from $196 million, or $1.69 a share, last year.

Further, Regeneron's GAAP research and development expenses were $510 million for the second quarter, down from $560 million last year due to a $75 million payment made under an agreement with Intellia Therapeutics Inc.